Background. Anti-r-HuEpo associated PRCA developed in patients received subcutaneous injection of r-HuEpo for treatment of renal anemia in chronic kidney disease. This adverse immunological effect of r-HuEpo causes sudden loss of r-HuEpo efficacy, low circulating reticulocyte count and bone marrow biopsy shows an absence of erythroid precursor cells with normal cell population of non-erythroid lineage. There are postulation cause of anti-r-HuEpo associated PRCA including genetic factor, immunogenicity factor, storage and handlings factor and formulation of r-HuEpo product. Previous observation of our report showed an aggregation of HLA-DRB1 * 09 in four anti-rHuEpo associated PRCA cases. This allele is rare in Caucasian (<1%) but more common in Thai population (8.4-12.5%). This study was aimed to investigate the possible association between HLA-DRB1 * 09 or other specific HLA and anti-r-HuEpo associated PRCA. Methods. Twenty two cases of proven anti-r-HuEpo associated PRCA were recruited and studied retrospectively based on the incidence report of serious adverse drug reaction. The EDTA bloods were drawn for HLA typing using sequence specific primer polymerase chain reaction (SSP-PCR). The HLA data of 1,800 potential cadaveric kidney transplantation recipients in the waiting list as chronic kidney disease control and 1,500 potential bone marrow stem cell donors in national stem cell registry as healthy population control were retrieved from the database of Thai Red Cross for comparison. Results. The distribution of gene frequency of HLA-A, -B, -DR and -DQ alleles in anti-r-HuEpo associated PRCA cases showed high gene frequency of HLA-A
Introduction
Recombinant human erythropoietin (r-HuEpo) has been used in clinical practice since the late 1980s to improve anaemia caused by erythropoietin deficiency in chronic kidney disease. Although r-HuEpo improves mortality and morbidity associated with anaemia of the patients, the adverse immunological effect of this agent has been reported. After the introduction of r-HuEpo, sporadic cases of the anti-r-HuEpo antibody developed with the subcutaneous administration have been identified [1] [2] [3] . Subsequently, 13 patients with chronic kidney disease, in whom loss of rHuEpo efficacy and blood transfusion-dependent anaemia occurred due to pure red cell aplasia (PRCA) after an initial 1546 K. Praditpornsilpa et al. response to subcutaneous use of r-HuEpo, have been studied. Anti-r-HuEpo has been demonstrated as the proximate cause of PRCA [4] . Patients with anti-r-HuEpo-associated PRCA suddenly experience a loss of efficacy of treatment and simultaneously have decreases in haemoglobin and circulating reticulocyte count. The bone marrow biopsy from these patients showed an absence of erythroid precursor cells with normal cell population of non-erythroid lineage. The anaemia in patients who had anti-r-HuEpo-associated PRCA is more severe than anaemia of chronic kidney disease at the same stage of disease, indicating the crossreactivity between r-HuEpo and native erythropoietin by the homology of the molecule. The anti-r-HuEpo antibodies are directed against the peptide of r-HuEpo molecule rather than the carbohydrate moiety and cause loss of rHuEpo efficacy by the neutralizing effect. Established risk factors for anti-r-HuEpo-associated PRCA include subcutaneous administration [5] and the presence of leachates from uncoated stoppers in formulation containing polysorbate 80 [6] . Theoretically, the break of tolerance by repeated subcutaneous injection of r-HuEpo initiated by the allorecognition involves the major histocompatibility. Previous observation of our report showed an aggregation of HLA-DRB1 * 09 in four anti-r-HuEpo-associated PRCA cases [7] . This allele is rare in Caucasian (<1%) but more common in the Thai population (8.4-12.5%) [8] . Previous studies have shown that HLA genes influence immune response in relation to drug treatment [9, 10] . This study was aimed to investigate the possible association between HLA-DRB1 * 09 or other specific HLA-and anti-r-HuEpoassociated PRCA.
Patients and methods
The study was performed under a protocol approved by the King Chulalongkorn Memorial Hospital ethical committee. Twenty-two cases of proven anti-r-HuEpo-associated PRCA were recruited and studied retrospectively based on the incidence report of serious adverse drug reaction. All cases had the essential features [11, 12] for the diagnosis of anti-r-HuEpo-associated PRCA which included (1) sudden onset of loss of efficacy of r-HuEpo, (2) low reticulocyte count (<10 × 109/L) and (3) positive for the anti-r-HuEpo antibody by radioimmunoprecipitation, using of 125 Iodinated erythropoietin as previously described [13, 14] , and the bone marrow biopsy showed normocellularity and the absence of erythroid precursor (<5% of erythroblast in bone marrow) with normal myeloid and megakaryocytic lineages. The CFU-E bioassay was done in the sera of 14 cases and all showed the neutralizing effect towards erythroid precursor. The EDTA bloods were drawn for the HLA typing after informed consent. Genomic a Patients who received uncoated syringe alpha form r-HuEpo at the time anti-r-HuEpo-associated PRCA was diagnosed. b Sera sample which the CFU-E bioassay was done with neutralizing result. c Patients who received beta form r-HuEpo at the time anti-r-HuEpo-associated PRCA was diagnosed.
DNA was isolated from white blood cells in EDTA blood samples. The HLA typing was performed using the intermediate resolution DNA typing using a sequence-specific primer polymerase chain reaction (SSP-PCR). The HLA data of 1800 potential cadaveric kidney transplantation recipients in the waiting list as chronic kidney disease control and 1500 potential bone marrow stem cell donors in the national stem cell registry as healthy population control were retrieved from the database of the Thai Red Cross Society for comparison.
Statistical methods
Statistical analysis was performed by using the Statistical Package for the Social Science version 11.1 (SPSS, Inc., Chicago, IL, USA) to evaluate whether there was a significant difference of HLA gene frequency between each population. The chi-square test was used to compare two data sets and ANOVA was used to compare more than two sets of data. A P-value of <0.05 was considered significant. The odds ratio was calculated when any HLA gene frequency was found to be significantly different.
Results

HLA data in anti-r-HuEpo-associated PRCA cases
All cases of anti-r-HuEpo-associated PRCA in this study were Thai with a mean age of 56.9 ± 16.9 years (ranged 17-82 years) and had mean exposure of r-HuEpo before loss of efficacy of 9.9 ± 3.2 months ( (Table 2) . HLA-DQ is a low polymorphism HLA and has association with HLA-DR.
Comparison of HLA of anti-r-HuEpo-associated PRCA, cadaver kidney transplant waiting list and national stem cell registry donor
There were no significant differences of HLA gene frequency which found in anti-r-HuEpo-associated PRCA cases between the potential cadaveric kidney transplantation recipients in the waiting list and the potential bone marrow stem cell donors in national stem cell registry Fig. 1 . The allele frequency of HLA of potential cadaver kidney transplant recipients in the waiting list (n = 3600), Thai national stem cell donors in the registry (n = 3000) and anti-r-HuEpo-associated PRCA cases (n = 44). * P = 0.001.
(P ≥ 0.05) (Figure 1 ). There was significant difference of HLA-DRB1 * 09 gene frequency (P < 0.001) between anti-r-HuEpo-associated PRCA cases, and potential cadaveric kidney transplantation in the waiting list or potential national stem cell registry donor ( Table 3 ). The odds ratio of HLA-DRB1 * 09 allele for anti-r-HuEpo-associated PRCA was 2.89 (95% CI: 1.88-4.46; P-value: <0.001) ( Table 4) .
Discussion
Repeated subcutaneous injection of r-HuEpo pharmacologic doses over an extended period of time induces an immune response. The induction of an immune response to r-HuEpo results in an autoimmune reaction to the Table 3 . Frequency of HLA alleles in anti-r-HuEpo-associated PRCA cases (n = 44), Thai national stem cell donor (n = 3000) and potential cadaver kidney transplant recipient (n = 3600) and P-values from comparing gene alleles frequencies
Alleles
Anti-r-HuEpo-associated PRCA (n = 44)
Thai national stem cell donor (n = 3000)
Potential cadaver kidney transplant recipient (n = 3600) endogenous native form. There are evidences that other biopharmaceutical agents namely G-CSF, GM-CSF, interferon α and interferon β have potential immunogenicity as antibodies to the recombinant protein developed in patients using the agents have been reported [15] , only the neutralization effect of the anti-r-HuEpo antibody which cross-reacts with the native molecule has been demonstrated. Our data showed that most of the anti-r-HuEpo-associated PRCA cases were diagnosed by the time of using alpha r-HuEpo, yet the use of beta r-HuEpo did not exclude the possibility of the condition. A leachate theory was developed, which explains the release of the organic compound leached from the exposure of polysorbate 80 as preservative to the uncoated stoppers in pre-filled syringes as the cause of the immunogenicity, and that the use of Teflon-coated stopper pre-filled syringes of r-HuEpo reduces the risk of the antir-HuEpo antibody in European countries. Our data showed that yet the use of Teflon-coated stopper pre-filled syringe that was free from leachate did not exclude risk of the neutralizing antibody as 11 cases received the coated stopper during the diagnosis of anti-r-HuEpo-associated PRCA, and this disparity of the prevalence between ours and the European population might be explained by HLA genetic polymorphism. By typing the HLA alleles expressed by individual antir-HuEpo-associated PRCA cases compared to the HLA alleles of potential kidney transplant recipients in the waiting list, which represent the chronic kidney disease population, and HLA alleles of the national stem cell donor registry, which represent the normal healthy population, there was an association between the HLA-DRB1
P-value
* 09 and the risk of anti-r-HuEpo-associated PRCA. The presence of HLA-DRB1 * 09 in anti-r-HuEpo-associated PRCA associated with HLA-DQB1 * 0309 (HLA-DRB1 * 09-DQB1 * 0309) as all PRCA cases who had HLA-DRB1 * 09 also had HLA-DQB1
* 0309. This finding demonstrated the genetic linkage between these two HLA alleles. The non-statistical significant difference of genotypic HLA alleles between potential kidney transplant recipient and national stem cell donor allowed us to conclude that the higher specific gene frequencies in anti-r-HuEpo-associated PRCA cases were not caused by the chronic kidney disease genetic risk of the population. A recent case-control study of the association between HLA gene and anti-r-HuEpo-associated PRCA in another set of population, mainly Caucasian in Europe and Canada, concurred with our findings as HLA-DR B1 * 9 occurred at a significant higher frequency in the antibodypositive PRCA case compared to control [16] .
The association of HLA and autoimmune diseases is well known and widely studied across the population worldwide, and found to be important in prediction of disease susceptibility. Also the specific HLA has been shown to be associated with drug hypersensitivity, demonstrating the significance of HLA in the immune allorecognition process. Analysis of population-specific distribution of HLA alleles is proven to be important in finding out disease susceptibility or resistance in specific ethnic groups as different population exhibit different frequency distributions of HLA alleles. A recent study showed the association between HLA-DRB1 * 09 and DQ-B1 * 0303 and type 1 diabetes mellitus [17] in the Asian population. Our finding of the association of HLA-DRB1 * 09-DQB1 * 0309 and anti-rHuEpo-associated PRCA may explain why there is more prevalence of anti-r-HuEpo-associated PRCA cases in our population compared with Caucasian, as this allele is rare in Caucasians. The concepts of specificities of HLA being involved in selection of potentially autoreactive T-cell specificities, and peripheral amplification of the potentially autoreactive T-cells to r-HuEpo which cross-react to native erythropoietin molecule, both need further study in another set of population where the frequency of HLA-DRB1 * 09 is comparable.
In summary, the anti-r-HuEpo antibody developed after subcutaneous injection of r-HuEpo exerted the potential immunogenicity of biopharmaceutical agent that was related to specific HLA for the allorecognition process. The present study indicated the contribution of HLA genotype to the genetic susceptibility to anti-r-HuEPO-associated PRCA. The HLA-DRB1 * 09-DQB1 * 0309 showed the association with anti-r-HuEpo-associated PRCA and may be used in identifying the risk of the patients.
